Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anzutresgene autoleucel + mRNA-4203
- Development stage
- Unknown
- Lead developer
- Immatics
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intravenous
01
Overview
anzutresgene autoleucel + mRNA-4203 (IMA203 + mRNA-4203) is an investigational combination immunotherapy being co-developed by Immatics and Moderna. The regimen pairs anzutresgene autoleucel (formerly IMA203), an autologous T-cell receptor engineered T-cell (TCR-T) therapy, with mRNA-4203, an mRNA-based cancer vaccine. Both components target the cancer-testis antigen PRAME (Preferentially Expressed Antigen in Melanoma). Anzutresgene autoleucel consists of the patient's own T cells engineered to recognize PRAME-derived peptides presented by HLA-A*02:01 on tumor cells. mRNA-4203 is a lipid nanoparticle (LNP)-encapsulated mRNA vaccine encoding PRAME, designed to act as a cell therapy enhancer by driving the activation and proliferation of the engineered TCR-T cells in vivo. The combination is being evaluated in a Phase 1a/b clinical trial for patients with HLA-A*02:01-positive, previously treated, unresectable or metastatic cutaneous melanoma or synovial sarcoma.
- Other names
- ACTengine IMA203 + mRNA-4203anzu-cel + mRNA-4203
Beyond the preview
Go deeper on anzutresgene autoleucel + mRNA-4203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anzutresgene autoleucel + mRNA-4203.